JP2016540503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540503A5 JP2016540503A5 JP2016532031A JP2016532031A JP2016540503A5 JP 2016540503 A5 JP2016540503 A5 JP 2016540503A5 JP 2016532031 A JP2016532031 A JP 2016532031A JP 2016532031 A JP2016532031 A JP 2016532031A JP 2016540503 A5 JP2016540503 A5 JP 2016540503A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody polypeptide
- antibody
- seq
- emitters
- polypeptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1320408.6 | 2013-11-19 | ||
| GB1320408.6A GB2520353A (en) | 2013-11-19 | 2013-11-19 | Antibody polypeptides and uses thereof |
| GB201401973A GB201401973D0 (en) | 2014-02-05 | 2014-02-05 | Antibody polypeptides and uses thereof |
| GB1401973.1 | 2014-02-05 | ||
| PCT/GB2014/053420 WO2015075445A1 (en) | 2013-11-19 | 2014-11-19 | Humanised anti kallikrein-2 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181801A Division JP7051777B2 (ja) | 2013-11-19 | 2019-10-02 | ヒト化抗カリクレイン-2抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540503A JP2016540503A (ja) | 2016-12-28 |
| JP2016540503A5 true JP2016540503A5 (cg-RX-API-DMAC10.html) | 2017-12-28 |
| JP6599859B2 JP6599859B2 (ja) | 2019-10-30 |
Family
ID=52114029
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532031A Active JP6599859B2 (ja) | 2013-11-19 | 2014-11-19 | ヒト化抗カリクレイン−2抗体 |
| JP2019181801A Active JP7051777B2 (ja) | 2013-11-19 | 2019-10-02 | ヒト化抗カリクレイン-2抗体 |
| JP2022003634A Active JP7592654B2 (ja) | 2013-11-19 | 2022-01-13 | ヒト化抗カリクレイン-2抗体 |
| JP2024201463A Pending JP2025019101A (ja) | 2013-11-19 | 2024-11-19 | ヒト化抗カリクレイン-2抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181801A Active JP7051777B2 (ja) | 2013-11-19 | 2019-10-02 | ヒト化抗カリクレイン-2抗体 |
| JP2022003634A Active JP7592654B2 (ja) | 2013-11-19 | 2022-01-13 | ヒト化抗カリクレイン-2抗体 |
| JP2024201463A Pending JP2025019101A (ja) | 2013-11-19 | 2024-11-19 | ヒト化抗カリクレイン-2抗体 |
Country Status (24)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2771037T3 (en) | 2011-10-28 | 2016-11-14 | Fredax Ab | Therapeutics and uses thereof |
| JP6308954B2 (ja) | 2012-03-05 | 2018-04-11 | オサケユキテュア・アークティック・パートナーズ・アクチボラゲットOy Arctic Partners Ab | 前立腺癌のリスク及び前立腺容積を予測する方法及び装置 |
| WO2015075445A1 (en) * | 2013-11-19 | 2015-05-28 | Fredax Ab | Humanised anti kallikrein-2 antibody |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| CN114740202A (zh) | 2014-03-28 | 2022-07-12 | 欧普科诊断有限责任公司 | 与前列腺癌的诊断有关的组合物和方法 |
| EP3253800B1 (en) | 2015-03-27 | 2021-03-03 | Opko Diagnostics, LLC | Prostate antigen standards and uses thereof |
| CA2982262A1 (en) | 2015-04-29 | 2016-11-03 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| US20180326102A1 (en) * | 2015-11-18 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| RS67792B1 (sr) | 2016-12-01 | 2026-03-31 | Regeneron Pharma | Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| SG11201908998XA (en) * | 2017-03-30 | 2019-10-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
| CN110997013B (zh) | 2017-07-24 | 2022-09-20 | 瑞泽恩制药公司 | 抗cd8抗体和其用途 |
| ES3075769T3 (en) | 2019-05-10 | 2026-08-07 | Janssen Biotech Inc | Macrocyclic chelators and methods of use thereof |
| TW202118792A (zh) * | 2019-07-26 | 2021-05-16 | 美商健生生物科技公司 | 抗hk2嵌合抗原受體(car) |
| CR20220025A (es) | 2019-07-26 | 2022-05-04 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| PE20230389A1 (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| JP7797469B2 (ja) * | 2020-07-17 | 2026-01-13 | ヤンセン バイオテツク,インコーポレーテツド | 抗klk2抗体に対する抗イディオタイプ抗体 |
| TW202233244A (zh) | 2020-11-10 | 2022-09-01 | 美商健生生物科技公司 | 巨環化合物及其使用方法 |
| CN112608365B (zh) * | 2020-12-22 | 2021-07-30 | 吉林省特医食品生物科技有限公司 | 一种减轻体重的发酵型小分子肽及其制备方法和应用 |
| CN114790245B (zh) * | 2021-01-25 | 2026-08-11 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| CN116806159A (zh) * | 2021-01-27 | 2023-09-26 | 詹森生物科技公司 | 包含激肽释放酶相关肽酶2抗原结合结构域的免疫缀合物及其用途 |
| AU2022213825A1 (en) * | 2021-01-27 | 2023-09-14 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| AU2022214914A1 (en) * | 2021-01-28 | 2023-08-17 | Astria Therapeutics, Inc. | Plasma kallikrein antibodies and uses thereof |
| MX2023014069A (es) * | 2021-05-27 | 2024-03-15 | Janssen Biotech Inc | Composiciones y métodos para el tratamiento del cáncer de próstata. |
| EP4429718A1 (en) | 2021-11-09 | 2024-09-18 | Janssen Biotech, Inc. | Macrocyclic compounds and diagnostic uses thereof |
| WO2023084396A1 (en) | 2021-11-09 | 2023-05-19 | Janssen Biotech, Inc. | Macrocyclic compounds and methods of making the same |
| WO2023144723A1 (en) | 2022-01-26 | 2023-08-03 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| WO2025244971A1 (en) | 2024-05-20 | 2025-11-27 | Janssen Biotech, Inc. | Compositions and methods for the treatment of prostate cancer |
| WO2026161804A1 (en) | 2025-01-24 | 2026-07-30 | Janssen Biotech, Inc. | Methods for production of radioimmunoconjugates |
| WO2026163208A1 (en) | 2025-02-03 | 2026-08-06 | Utt Urine Topical Treatment Ltd | Drug delivery systems and articles for treating conditions and diseases of the patient's body cavities |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| US6379669B1 (en) | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| WO1998021365A2 (en) | 1996-11-14 | 1998-05-22 | Mayo Foundation For Medical Education And Research | Method for detection of metastatic prostate cancer |
| US7053042B1 (en) | 1999-07-29 | 2006-05-30 | Samuel Denmeade | Activation of peptide prodrugs by hK2 |
| WO2001012218A1 (en) | 1999-08-16 | 2001-02-22 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
| FI20002127A0 (fi) | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
| US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| CA2447695C (en) | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| AU2002362447A1 (en) * | 2001-10-03 | 2003-04-14 | University Of Rochester | Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2 |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| EP2347767A3 (en) | 2003-01-31 | 2013-06-12 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
| EP1610818A4 (en) * | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
| CN101094869A (zh) * | 2004-08-03 | 2007-12-26 | 戴埃克斯有限公司 | Hk1结合蛋白 |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
| CA2598454C (en) * | 2005-02-18 | 2013-04-09 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| SG177168A1 (en) | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
| CA2673366C (en) * | 2006-12-22 | 2017-12-19 | Phadia Ab | Novel prostate kallikrein allergen |
| JP2012505654A (ja) * | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| DK2771037T3 (en) * | 2011-10-28 | 2016-11-14 | Fredax Ab | Therapeutics and uses thereof |
| WO2015075445A1 (en) * | 2013-11-19 | 2015-05-28 | Fredax Ab | Humanised anti kallikrein-2 antibody |
| WO2023278463A1 (en) | 2021-06-29 | 2023-01-05 | Volastra Therapeutics, Inc. | Anti-enpp1 antibodies and uses thereof |
-
2014
- 2014-11-19 WO PCT/GB2014/053420 patent/WO2015075445A1/en not_active Ceased
- 2014-11-19 HU HUE14814696A patent/HUE043875T2/hu unknown
- 2014-11-19 PL PL14814696T patent/PL3071595T3/pl unknown
- 2014-11-19 SM SM20190338T patent/SMT201900338T1/it unknown
- 2014-11-19 ES ES14814696T patent/ES2728515T3/es active Active
- 2014-11-19 FI FIEP19161698.6T patent/FI3553088T3/fi active
- 2014-11-19 MX MX2016006561A patent/MX383543B/es unknown
- 2014-11-19 LT LTEP19161698.6T patent/LT3553088T/lt unknown
- 2014-11-19 KR KR1020237029468A patent/KR102894975B1/ko active Active
- 2014-11-19 KR KR1020167016169A patent/KR102442738B1/ko active Active
- 2014-11-19 AU AU2014351611A patent/AU2014351611B2/en active Active
- 2014-11-19 PT PT191616986T patent/PT3553088T/pt unknown
- 2014-11-19 ES ES19161698T patent/ES3068994T3/es active Active
- 2014-11-19 EP EP14814696.2A patent/EP3071595B1/en active Active
- 2014-11-19 HR HRP20260518TT patent/HRP20260518T1/hr unknown
- 2014-11-19 CA CA2930493A patent/CA2930493A1/en active Pending
- 2014-11-19 RS RS20190729A patent/RS58831B1/sr unknown
- 2014-11-19 SM SM20260181T patent/SMT202600181T1/it unknown
- 2014-11-19 IL IL311788A patent/IL311788B2/en unknown
- 2014-11-19 DK DK14814696.2T patent/DK3071595T3/da active
- 2014-11-19 IL IL297678A patent/IL297678B2/en unknown
- 2014-11-19 LT LTEP14814696.2T patent/LT3071595T/lt unknown
- 2014-11-19 DK DK19161698.6T patent/DK3553088T3/da active
- 2014-11-19 HR HRP20191095TT patent/HRP20191095T1/hr unknown
- 2014-11-19 RU RU2016124229A patent/RU2687163C1/ru active
- 2014-11-19 CN CN201480072422.8A patent/CN105980404B/zh active Active
- 2014-11-19 BR BR112016011025-0A patent/BR112016011025B1/pt active IP Right Grant
- 2014-11-19 PT PT14814696T patent/PT3071595T/pt unknown
- 2014-11-19 KR KR1020227003223A patent/KR102574537B1/ko active Active
- 2014-11-19 US US15/036,170 patent/US10100125B2/en active Active
- 2014-11-19 SI SI201431143T patent/SI3071595T1/sl unknown
- 2014-11-19 SI SI201432125T patent/SI3553088T1/sl unknown
- 2014-11-19 CN CN202011566401.5A patent/CN112898431B/zh active Active
- 2014-11-19 EP EP19161698.6A patent/EP3553088B1/en active Active
- 2014-11-19 RS RS20260462A patent/RS68011B1/sr unknown
- 2014-11-19 JP JP2016532031A patent/JP6599859B2/ja active Active
- 2014-11-19 EP EP26156119.5A patent/EP4741015A3/en active Pending
- 2014-11-19 PL PL19161698.6T patent/PL3553088T3/pl unknown
-
2016
- 2016-05-11 IL IL245617A patent/IL245617B/en active IP Right Grant
- 2016-05-19 MX MX2021007006A patent/MX2021007006A/es unknown
-
2018
- 2018-08-30 US US16/117,522 patent/US11230609B2/en active Active
-
2019
- 2019-06-20 CY CY20191100645T patent/CY1121900T1/el unknown
- 2019-10-02 JP JP2019181801A patent/JP7051777B2/ja active Active
-
2020
- 2020-07-20 AU AU2020207775A patent/AU2020207775B2/en active Active
- 2020-11-04 IL IL278493A patent/IL278493B2/en unknown
-
2021
- 2021-09-16 US US17/476,683 patent/US12404343B2/en active Active
-
2022
- 2022-01-13 JP JP2022003634A patent/JP7592654B2/ja active Active
-
2023
- 2023-08-30 AU AU2023222879A patent/AU2023222879A1/en active Pending
-
2024
- 2024-11-19 JP JP2024201463A patent/JP2025019101A/ja active Pending
-
2025
- 2025-09-28 IL IL323633A patent/IL323633A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7051777B2 (ja) | ヒト化抗カリクレイン-2抗体 | |
| Kenanova et al. | Tailoring antibodies for radionuclide delivery | |
| Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
| Olafsen et al. | Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody | |
| JP2017532952A5 (cg-RX-API-DMAC10.html) | ||
| Chester et al. | Engineering antibodies for clinical applications in cancer | |
| JP2014530898A5 (cg-RX-API-DMAC10.html) | ||
| Accardi et al. | Antibodies in single-chain format against tumour-associated antigens: present and future applications | |
| JP2018531045A5 (cg-RX-API-DMAC10.html) | ||
| GB2520353A (en) | Antibody polypeptides and uses thereof | |
| RU2018115734A (ru) | Полипептиды антител и их применение | |
| Hauck et al. | Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia | |
| JP2018531045A6 (ja) | 抗体ポリペプチド及びそれらの使用 | |
| Hermanto et al. | Preparation of F (ab’) 2 trastuzumab fragment for Radioimmunoconjugate synthesis of 177 Lu-DOTA-F (ab’) 2-trastuzumab | |
| Cabanillas-Bernal et al. | variable single domains (VNARs): broadly neutralizing tools for | |
| CA2696634A1 (en) | Monoclonal antibodies against human acidic and basic ferritins and nucleotide and amino acid sequences thereof | |
| BR112018002451B1 (pt) | Região de dobramento de aminoácidos e composição farmacêutica |